Doctors at Rambam Health Care Campus in Haifa, Israel, have performed what they describe as the first procedure using MRI-guided focused ultrasound to treat opioid addiction without surgery or anesthesia.
The patient, identified only as H., is a man in his forties who developed an addiction after being prescribed opioids for a neck injury years earlier. According to Rambam physicians, he had been consuming approximately 130 pills per day before seeking treatment. Using technology developed by Israeli firm Insightec, doctors targeted the nucleus accumbens—the brain's reward center—and modulated its electrical activity.
The procedure took less than 20 minutes. Within one week, H. tested negative for opioids and reported a self-described craving level of zero out of ten. His medical team noted he also reduced his smoking from three packs per day to near-zero almost immediately after the treatment, though researchers said further study would be needed to understand those effects.
The American Medical Association reports that overdose deaths dropped from over 110,000 in 2023 to roughly 75,000 in 2024. However, the association notes that progress remains limited, with substitute medications often difficult for patients to access due to insurance barriers and regulatory requirements. Gradual opioid tapering currently succeeds in approximately 5% of cases.
What the Right Is Saying
Conservative health economists and addiction specialists note that current medication-assisted treatments remain underutilized due to regulatory restrictions rather than lack of effectiveness. The American Society of Addiction Medicine has called for streamlined prescribing rules for drugs like buprenorphine, arguing that reducing bureaucratic barriers would do more to address the crisis than new technologies alone.
Senator Bill Cassidy of Louisiana, a physician who chairs the Senate Health Committee, said in a statement that breakthrough treatments must be evaluated through rigorous clinical trials before widespread adoption. "We cannot allow enthusiasm to outpace evidence," Cassidy wrote. The Goldwater Institute has argued that FDA approval timelines create delays that prevent patients from accessing innovative therapies, calling for accelerated pathways for non-surgical addiction treatments.
What the Left Is Saying
Democratic health policy advocates have long pushed for expanded access to medication-assisted treatment and new approaches to addiction care. Progressive groups argue that insurance companies and pharmacy benefit managers have created systemic barriers that prevent patients from accessing proven therapies, contributing to the ongoing crisis despite medical advances.
Congressional Democrats including Senator Jeanne Shaheen of New Hampshire and Representative Dan Crenshaw of Texas—who has spoken publicly about his own experience with PTSD and opioids—have co-sponsored legislation aimed at expanding access to addiction treatment. The National Harm Reduction Coalition said the Israeli procedure represents a potential paradigm shift, but emphasized that access would depend on whether insurance companies cover the treatment and whether Medicare and Medicaid programs include it in their benefit structures.
What the Numbers Show
The opioid epidemic costs the United States an estimated $60 billion annually in healthcare, lost productivity, and criminal justice expenses, according to federal health statistics. Current treatment approaches show limited success rates: gradual tapering succeeds approximately 5% of the time, while medication-assisted treatment remains out of reach for many patients due to insurance prior authorization requirements.
The Rambam procedure is not yet approved by the FDA or any regulatory body outside Israel. Insightec's ultrasound technology has received FDA clearance for treating movement disorders such as essential tremor and Parkinson's disease tremors, but addiction treatment would require separate clinical trials and approval processes—a pathway that typically takes years and costs hundreds of millions of dollars.
The American Medical Association reports that while overdose deaths declined from over 110,000 in 2023 to roughly 75,000 in 2024, the emergence of new synthetic opioids and drug combinations continues to complicate treatment efforts. Insurance coverage for novel addiction treatments varies widely, with many plans excluding procedures deemed experimental.
The Bottom Line
The Israeli procedure represents an early-stage medical development rather than a proven treatment ready for widespread use. Researchers at Rambam emphasized that much more study is needed before the approach could be considered standard care, noting that a single patient case does not establish safety or efficacy.
For policymakers, the development raises questions about how to balance innovation with evidence-based regulation. If future clinical trials confirm the technique's effectiveness, lawmakers would face decisions about insurance coverage, Medicare and Medicaid reimbursement rates, and whether the procedure should be classified as a medical treatment or a specialized therapy requiring additional oversight.
What happens next will depend on results from larger studies. Insightec has not announced plans for FDA trials targeting addiction, though company representatives said they are in discussions with research institutions about potential partnerships. The broader implications for healthcare policy—and whether this approach could eventually address conditions like severe depression and OCD—remain years away from resolution.